



ImmunoCellular  
Investor Relations Department  
23622 Calabasas Road  
Suite 300  
Calabasas, CA 91302  
United States

Visit IR website [↗](#)

#### AMEX: IMUC

Last Trade:	0.29
Trade Time:	3:59 PM ET January 22, 2018
Change:	-0.01 <span style="color:red">↓</span> (1.628%)
Day Range	0.29 - 0.30
52-Week Range	0.17 - 3.68
Volume	762,805

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- December 13, 2017*  
[ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program](#)
- November 22, 2017*  
[ImmunoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017](#)
- November 21, 2017*  
[ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results](#)
- November 17, 2017*  
[ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017](#)
- October 3, 2017*  
[ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET](#)

## Financials [\[ View all \]](#)

- March 9, 2017*  
[Annual Report \(10-K\)](#)
- April 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- November 21, 2017*  
[Quarterly Report \(10-Q\)](#)
- August 14, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 15, 2017*  
[Quarterly Report \(10-Q\)](#)